Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Chlorhexidine Gluconate

FDA-approved product (solution, topical), marketed as Bioscrub, Brian Care, Chg Scrub and 17 more.

Registered studies
50+
Lab records
5
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Chlorhexidine Gluconate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Eye infection
  • Gingivitis
  • Infection
  • Periodontitis
  • Pharyngitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives and antiseptics for local oral treatment; Antiinfectives; Biguanides and amidines; Medicated dressings with antiinfectives; Antiseptics
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC A01AB03; WHO ATC D08AC02; WHO ATC D08AC52; WHO ATC D09AA12; WHO ATC S01AX09; WHO ATC S02AA09; WHO ATC S03AA04

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli58.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae69.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis42.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 1 lab record
  • E. coli: measured active in 3 of 3 lab records
  • K. pneumoniae: measured active in 1 of 1 lab record
Open Chlorhexidine Gluconate in ChEMBL Registered studies below
Show the 5 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Chlorhexidine Gluconate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees

    NCT01105767 · start 2010-05

    Registered record
    Registry ID
    NCT01105767
    Conditions
    Staphylococcus Aureus; MRSA Skin Infections; Staphylococcal Skin Infections
    Interventions
    Chlorhexidine gluconate; Supplemental training, education and hygiene
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-05
    Completion
    2012-01
    Enrolment
    30,209

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus; MRSA Skin Infections; Staphylococcal Skin Infections
    InterventionChlorhexidine gluconate; Supplemental training, education and hygiene
    PhaseNot applicable
    Registry statusCompleted

  • Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)

    NCT00980980 · start 2009-09

    Registered record
    Registry ID
    NCT00980980
    Conditions
    Methicillin-resistant Staphylococcus Aureus
    Interventions
    Chlorhexidine bath and nasal mupirocin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-09
    Completion
    2011-09
    Enrolment
    74,256

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethicillin-resistant Staphylococcus Aureus
    InterventionChlorhexidine bath and nasal mupirocin
    PhaseNot applicable
    Registry statusCompleted

  • Strategies To Prevent Pneumonia 2 (SToPP2)

    NCT00893763 · start 2008-09

    Registered record
    Registry ID
    NCT00893763
    Conditions
    Infections, Hospital; Ventilator-Associated Pneumonia; Mechanical Ventilation Complication
    Interventions
    Pre-intubation CHX; Control
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-09
    Completion
    2012-06
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Hospital; Ventilator-Associated Pneumonia; Mechanical Ventilation Complication
    InterventionPre-intubation CHX; Control
    PhasePhase 2
    Registry statusCompleted

  • Reducing Catheter-Related Bloodstream Infections in the ICU With a Chlorhexidine-Impregnated Sponge (BIOPATCH)

    NCT00548132 · start 2006-02

    Registered record
    Registry ID
    NCT00548132
    Conditions
    Catheter-related Bloodstream Infection
    Interventions
    Chlorhexidine-impregnated foam dressing
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-02
    Completion
    2009-05
    Enrolment
    1,088

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCatheter-related Bloodstream Infection
    InterventionChlorhexidine-impregnated foam dressing
    PhasePhase 4
    Registry statusCompleted

  • Oral Hygiene With Chlorhexidine and Incidence of Ventilator-Associated Pneumonia in Children Submitted to Heart Surgery

    NCT00829842 · start 2006-02

    Registered record
    Registry ID
    NCT00829842
    Conditions
    Ventilator Associated Pneumonia; Nosocomial Pneumonia; Heart Surgery
    Interventions
    oral hygiene; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-02
    Completion
    2006-02
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia; Nosocomial Pneumonia; Heart Surgery
    Interventionoral hygiene; placebo
    PhasePhase 3
    Registry statusCompleted